AngioDynamics (NASDAQ:ANGO) SVP Warren Nighan, Jr. Sells 23,370 Shares of Stock

AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. sold 23,370 shares of AngioDynamics stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

AngioDynamics Stock Performance

Shares of ANGO opened at $14.79 on Friday. The firm has a market cap of $611.27 million, a PE ratio of -17.00 and a beta of 0.34. AngioDynamics, Inc. has a 52-week low of $8.36 and a 52-week high of $15.19. The business’s 50 day moving average price is $12.81 and its two-hundred day moving average price is $11.50.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. The company had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Research analysts predict that AngioDynamics, Inc. will post -0.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ANGO. Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Canaccord Genuity Group upped their price target on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. HC Wainwright increased their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $19.50.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors have recently added to or reduced their stakes in ANGO. Farther Finance Advisors LLC increased its stake in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of AngioDynamics in the 4th quarter worth approximately $27,000. State of Wyoming bought a new position in shares of AngioDynamics in the second quarter valued at approximately $31,000. Russell Investments Group Ltd. grew its holdings in shares of AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 4,268 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.